Arotinolol: world first introduction of this α + β-blocker by Sumitomo in Japan
Transcript of Arotinolol: world first introduction of this α + β-blocker by Sumitomo in Japan
Arotinolol: world first introduction of this Q + ~-blocker by Sumitomo in Japan
Pharmacology Arotinolol. Anon. Drugs of the Future 10: 491. 1985 Antihypertensive effects of arotinolol (S-596) a new adrenergic
blocking agen!. in experimental hypertensive rats. Hara T. et al. Folia Pharmacologica Japonica 82: 103. 1983
Effects of a new beta-adrenoceptor blocking agen!. S-596 (Arotinolol). on isolated dog coronary arteries. Sakanashi M. et al. Archives Internationa/es de Pharmacodynamic et de Therapie 263: 208. 1'183
Hemodynamic Effects of Arotinolol in Anesthetized Dogs and its Affinities for Adrenoceptors in Vitro. Hashimoto H. et al. Archives Internationales de Pharmacodynamie et de Therapie 267: 23. 1984
StudIes on concurrent alpha and beta-adrenoceptor blocking action of S-5'16 (Arotinolol). Takekoshi N. et al. Japanese Heart Journal 24: 925-935. 1983
General pharmacological studies on arotinolol (s..596). a betaadrenoceptor blocking drug. Hara Y. et al. Pharmacometrics 27: 1037. 1984
Possible alpha-adrencoceptor blocking activity of arotinolol (s..596). a new beta-adrenoceptor blocking agent in isolated dog coronary artery. Sakanashi M. et al. Pharmacology 29: 204. 1984
Acute hypotension action of a beta-adrenoceptor blocking agent_ arotinolol in normotensive. OOCA-saline and renal hypertensive rats. Miyano T. et al. Pharmacometrics 28: 307. 1984
Effects of chronic administration of arotinolol (ARL. s..596) on strokeprone spontaneously hypertensive rats (SHRSP) (I) blood pressure. heart rate and biochemical values. Izumi R. et al. Pharmacometrics 28: 455. 1984
Effects of chronic administration of arotinolol (ARL, s..S96) on strokeprone spontaneously hypertensive rats (SHRSP) (2) histopathological studies. Sekine I. et al. Pharmacometrics 28: 459. 1984
Effects of chronic administration of arotinolol (ARL. s..596) on strokeprone spontaneously hypel1ensive rats (SHRSP) (3) studies on catecholamine contents in heart and adrenal gland. Matsuo K. et al. Pharmacometrics 28: 467. 1984
Effects of arotinolol (s..596) on isolated and perfused rat hearts. Sakanashi M. et al. Pharmacometrics 28: 709. 1984
Adrenoceptor blocking effects of arotinolol. a new combined alphaand beta-adrenoceptor blocking agent. Miyagishi A. et al. Archives Internationales de Pharmacodynamie et de Therapie 271: 249. 1984
Chronic effects of arotinolol (s..596) in spontaneously hypel1ensive rats. Kishi K. et al. Journal of Pharmacobio-Dynamics 8: 50. 1985
Effect of ophthalmic administration of s..596 (arotinolol) on intraocular pressure and haemodynamic in healthy volunteers: Comparison with timolol. Nakashima M. et al. European Journal of Clinical Pharmacology 28: 391. 1985
Alpha-blockade and vasodilation induced by nipradilol. arotinolol and labetalol in pithed rats. Nakagawa Y. et al. The Japanese Journal of Pharmacology 39: 481. 1985
Mechanism of the hypotensive effect of a new B-adrenergic blocking drug. arotinolol (s..596) in anesthetized rabbits. Nakahara H. et al. Archives Internationales de Pharmacodynamie et de Therapie 277: 253. 1985
0156·2703/86/0830-0019/0$01.00/0 © ADIS Press INPHARMA® 30 Aug 1986 19